Evaluation of Ovarian Reserve with AMH Level in Patients with Well-Differentiated Thyroid Cancer Receiving Radioactive Iodine Ablation Treatment
- PMID: 27711957
- DOI: 10.1055/s-0042-115639
Evaluation of Ovarian Reserve with AMH Level in Patients with Well-Differentiated Thyroid Cancer Receiving Radioactive Iodine Ablation Treatment
Abstract
Introduction: Radioactive iodine (RAI) ablation treatment is used for patients diagnosed with well-differentiated thyroid cancer in order to reduce the risk of recurrence. RAI ablation treatment can adversely affect gonads in males and females. In this study, we aimed to determine ovary damage and infertility risk due to RAI, using serum anti-Müllerian hormone (AMH) level, in females who received RAI ablation treatment. Materials and Methods: 45 female patients who have not gone through the menopause and had received RAI ablation treatment for well-differentiated thyroid cancer in premenopausal period, and 40 healthy females as control groups were included in this study. The serum AMH, follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), thyroid stimulating hormone (TSH) and creatinine levels of the patients included in the study were analyzed and compared to those of the control group with similar demographical characteristics. Results: No differences were found between the patient group and control group in terms of age, height, weight, body mass index, LH, E2 and creatinine. The difference in AMH, FSH and TSH between both groups were found to be significant. There was no statistically significant relation between the age and AMH levels. Similarly, no statistically significant relation between RAI exposure duration and AMH levels was determined. When the patients below and above the age of 35 were compared with regard to AMH (2.95±1.79 and 2.75±1.94, respectively) and FSH (5.45±1.63 and 5.99±3.06, respectively), the difference between them was found to be statistically insignificant. Oligo/anovulation was detected in 7 patients (15.6% of the patient group) after RAI treatment, 8 (17.8%) patients became pregnant after RAI treatment, and none of the patients, who were actively trying to get pregnant, were unable to achieve it. Conclusion: According to these results, it may be concluded that low AMH levels due to RAI treatment can cause damage to the ovaries of patients; nevertheless, considering the AMH levels and the absence of infertility in the patients, the infertility risk was found to be low.
© Georg Thieme Verlag KG Stuttgart · New York.
Similar articles
-
Effects of Radioactive Iodine Therapy on Ovarian Reserve: A Prospective Pilot Study.Thyroid. 2018 Dec;28(12):1702-1707. doi: 10.1089/thy.2018.0129. Epub 2018 Sep 29. Thyroid. 2018. PMID: 30156472
-
A Single Radioactive Iodine Treatment Has a Deleterious Effect on Ovarian Reserve in Women with Thyroid Cancer: Results of a Prospective Pilot Study.Thyroid. 2018 Apr;28(4):522-527. doi: 10.1089/thy.2017.0442. Epub 2018 Mar 13. Thyroid. 2018. PMID: 29466932
-
Longitudinal Analysis of the Effect of Radioiodine Therapy on Ovarian Reserve in Females with Differentiated Thyroid Cancer.Thyroid. 2020 Apr;30(4):580-587. doi: 10.1089/thy.2019.0504. Epub 2020 Feb 10. Thyroid. 2020. PMID: 31928168
-
The role of anti-Müllerian hormone in the pathogenesis and pathophysiological characteristics of polycystic ovary syndrome.Eur J Obstet Gynecol Reprod Biol. 2016 Apr;199:82-7. doi: 10.1016/j.ejogrb.2016.01.029. Epub 2016 Feb 10. Eur J Obstet Gynecol Reprod Biol. 2016. PMID: 26914398 Review.
-
The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008.Thyroid. 2010 Nov;20(11):1235-45. doi: 10.1089/thy.2009.0455. Thyroid. 2010. PMID: 21062195 Review.
Cited by
-
Cross-sectional and prospective study on anti-Müllerian hormone changes in a cohort of pre-menopausal women with a history of differentiated thyroid cancer.Thyroid Res. 2020 Jan 10;13:1. doi: 10.1186/s13044-020-0075-z. eCollection 2020. Thyroid Res. 2020. PMID: 31938042 Free PMC article.
-
GnRHa for Ovarian Protection and the Association between AMH and Ovarian Function during Adjuvant Chemotherapy for Breast Cancer.J Cancer. 2019 Jul 10;10(18):4278-4285. doi: 10.7150/jca.31859. eCollection 2019. J Cancer. 2019. PMID: 31413747 Free PMC article.
-
Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.Hum Reprod Update. 2022 May 2;28(3):417-434. doi: 10.1093/humupd/dmac004. Hum Reprod Update. 2022. PMID: 35199161 Free PMC article.
-
Thyroid cancer and pregnancy: a systematic ten-year-review.Gland Surg. 2024 Jun 30;13(6):1097-1107. doi: 10.21037/gs-24-52. Epub 2024 Jun 20. Gland Surg. 2024. PMID: 39015727 Free PMC article. Review.
-
Thyroid nodules and cancer during pregnancy, post-partum and preconception planning: Addressing the uncertainties and challenges.Best Pract Res Clin Endocrinol Metab. 2020 Jul;34(4):101363. doi: 10.1016/j.beem.2019.101363. Epub 2019 Nov 22. Best Pract Res Clin Endocrinol Metab. 2020. PMID: 31786102 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical